Abstract
Starting from a orexin 1 receptor selective antagonist 4,4-disubstituted piperidine series a novel potent 5-azaspiro[2.4]heptane dual orexin 1 and orexin 2 receptor antagonist class has been discovered. SAR and Pharmacokinetic optimization of this series is herein disclosed. Lead compound 15 exhibits potent activity against orexin 1 and orexin 2 receptors along with low cytochrome P450 inhibition potential, good brain penetration and oral bioavailability in rats.
Copyright © 2013 Elsevier Ltd. All rights reserved.
MeSH terms
-
Animals
-
Aza Compounds / chemistry*
-
Biological Availability
-
Brain / drug effects
-
Brain / metabolism
-
Cytochrome P-450 Enzyme Inhibitors
-
Cytochrome P-450 Enzyme System / metabolism
-
Drug Evaluation, Preclinical
-
Half-Life
-
Heptanes / chemical synthesis
-
Heptanes / chemistry*
-
Heptanes / pharmacokinetics
-
Orexin Receptors
-
Rats
-
Receptors, G-Protein-Coupled / antagonists & inhibitors*
-
Receptors, G-Protein-Coupled / metabolism
-
Receptors, Neuropeptide / antagonists & inhibitors*
-
Receptors, Neuropeptide / metabolism
-
Spiro Compounds / chemistry*
-
Structure-Activity Relationship
Substances
-
Aza Compounds
-
Cytochrome P-450 Enzyme Inhibitors
-
Heptanes
-
Orexin Receptors
-
Receptors, G-Protein-Coupled
-
Receptors, Neuropeptide
-
Spiro Compounds
-
Cytochrome P-450 Enzyme System